More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib …Phase Ib trial assessing the safety and tolerability of Genentech’s candidate, DSTA4637S, which combines Symphogen’s antibody with an antibiotic agent. Staphylococcus aureus infections are particularly deadly, with an annual incidence… November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2017 In the Age of Biological Therapeutics, Chemists move to ADCs …ADCs include the absence of data on unconjugated antibody testing, criteria for an acceptable amount of unconjugated antibody, and data relating to the drug-antibody ratio. Images from the author … February 23, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 26 Jul 2023 Antibody drug conjugates: BiVictriX drives a new era in cancer medicine …a monoclonal antibody – which binds to the cancer protein in a cell – attached to a linker, which delivers the anticancer drug once the antibody latches on to the… July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 20 Sep 2017 New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work… September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 1 Aug 2024 CureVac: From a failed drug to a €1.45 billion deal …the race with its first-generation COVID-19 vaccine, CVnCoV, it did not come first, and didn’t even finish the race. Indeed, CureVac faced significant setbacks with its COVID candidates, allowing Moderna… August 1, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Sponsored by Hub Organoids 12 Jul 2022 The organoid era: bringing patient-relevant preclinical models to the lab …in a large patient sample.” This led to the identification of a promising candidate. “An extended screen with CRC organoid models showed that the newly identified antibody effectively blocked tumor… July 12, 2022 - 7 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Aug 2025 10 oncology deals in 2025 spotlight where industry leaders are betting big …payments through 2028, and up to $7.6 billion in milestone payments. The partnership involves the co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types, as… August 5, 2025 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs …lead product candidate in alpha-1 antitrypsin deficiency (AATD) through a clinical milestone, progression of additional product candidates from the pipeline into the clinic, and demonstrating applicability of the RNA editing… November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jul 2025 Serial acquirer Concentra Biosciences on a buyout spree in 2025 …proceeds from its candidates KB-9558 and KB-7898 to treat cancer and autoimmune conditions, respectively, over the next two years. Plus, it includes all of the proceeds from its candidates KB-0742,… July 15, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Dec 2024 Idiopathic pulmonary fibrosis: Refoxy, Boehringer, Insilico, and more on the hunt for curative treatments …candidate One promising candidate is Refoxy Pharma’s FOXO3 therapy. The Cologne-based biotech made the news this morning after it secured €9.1 million ($9.58 million) in a financing round led by… December 4, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 6 Oct 2022 15 biotech companies shaking up the scene in Cambridge …major biotech and pharma hub. Antibody development is one of the strengths of the city thanks to the legacy of Cambridge Antibody Technologies, which pioneered the technology of phage display… October 6, 2022 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne …discontinuing two phase III trials testing AC Immune’s lead antibody drug candidate as an Alzheimer’s treatment. However, the candidate is still in an ongoing phase II trial for the prevention… May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email